Diagnosis and Staging Research
-
Can Artificial Intelligence Help See Cancer in New, and Better, Ways?Posted:
Researchers have been developing artificial intelligence (AI) tools that could make cancer imaging faster, more accurate, and more informative. But there are also questions about whether these tools are ready for doctors’ offices, whether they will actually help people, and whether that benefit will reach all—or only some—patients.
-
Cancer “Liquid Biopsy” Blood Test Gets Expanded FDA ApprovalPosted:
FDA has expanded the approved uses of the FoundationOne Liquid CDx blood test, known as a liquid biopsy, that can help doctors pick specific treatments for some people with cancer. When used in this way, the test is known as a companion diagnostic.
-
Artificial Intelligence Expedites Brain Tumor Diagnosis during SurgeryPosted:
A method that combines artificial intelligence with an advanced imaging technology can accurately diagnose brain tumors in fewer than 3 minutes during surgery, a new study shows. The approach can also accurately distinguish tumor from healthy tissue.
-
Using Artificial Intelligence to Classify Lung Cancer Types, Predict MutationsPosted:
Cancer researchers have trained a computer program to scan images of tissue samples to differentiate normal lung tissue from the two most common forms of lung cancer. The program also learned to detect cancer-related genetic mutations in the samples.
-
Liquid Biopsy: Using DNA in Blood to Detect, Track, and Treat CancerPosted:
Research studies show tests that analyze tumor DNA in blood, called liquid biopsies, may help detect cancer early, guide precision cancer treatment, and track treatment response.
-
Image-guided biopsy for diagnosis of prostate cancer can increase detection of high-risk tumorsPosted:
In the largest prospective study to date of image-guided technology for identifying suspicious regions of the prostate to biopsy, researchers compared the ability of this technology to detect high-risk prostate cancer with that of the current standard of unguided prostate biopsy.
-
NCI establishes Genomic Data Commons to facilitate identification of molecular subtypes of cancer and potential drug targetsPosted:
NCI is establishing the Genomic Data Commons to store, analyze and distribute cancer genomics data generated by NCI and other research organizations. The GDC will provide an interactive system for researchers to access data, with the goal of advancing the molecular diagnosis of cancer and suggest potential therapeutic targets based on genomic information.